Skip to NavigationSkip to content

Business Services

Veeva R&D Summit, Europe

Living with atrial fibrillation

Published on 23/04/18 at 11:05am

Tony Green discusses the difficulty in pinning down his diagnosis of the irregular heart rhythm condition, until his use of AliveCor’s KardiaMobile smartphone ECG device, at the recommendation of his cardiologist, proved to be a turning point on the way to better health.

How did your symptoms begin?

Top Ten most popular articles on Pharmafile.com this week

It's the end of another week and there's really been one story that has dominated the headlines – Takeda’s potential takeover of Shire. It should come as no surprise that our most viewed story of the week relates to the purchase.

The UK’s Royalties withholding tax consultation: Pushing extraterritorial boundaries

Published on 19/04/18 at 10:49am

Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border royalties.

The UK government has commenced a consultation regarding the scope of the royalty withholding regime applied in the UK. This may have a significant impact on multinational companies operating in the pharmaceutical sector who make UK sales other than through a UK permanent establishment or a UK tax resident entity.

Immunomedics’ whirlwind in the C-suite continues

Published on: 18/04/18

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, which eventually led to CEO, Cynthia Sullivan, and CSO, David Goldenberg, heading to the door.

Not long prior to this maelstrom, the company had lost its CFO, Peter Pfreundschuh, who decided to pursue other opportunities – ending up at Sucampo Pharmaceuticals, just before Mallinckrodt swooped to acquire it.

Frequency Therapeutics hires industry vet

Published on: 18/04/18

Frequency Therapeutics is a biotech with big ideas and it has made a big appointment to back up those ideas, by appointing William Chin to join the company as Chief Medical Officer.

Chin arrives at the company with a pretty illustrious past, having worked as Head of Science and Regulatory Affairs at PhRMA, having been a professor of medicine at Harvard Medical School and holding the position of SVP for Discovery Research and Clinical Investigation at Eli Lilly.

Care packaging: Inside the Falsified Medicines Directive

Published on 16/04/18 at 10:56am

When it comes to the pharmaceutical supply chain, patient safety has and will always be a primary concern for all parties involved. To tackle this ever-present risk in Europe, the ambitious solution has been to come together to form a region-wide safety net to ensure the utmost standards of product validity, in part by leveraging new innovations in medicinal packaging. And so, the Falsified Medicines Directive (FMD) was born.

Visit Us! DIA's Refreshed Homepage Design

Published date: 
13/04/2018
Summary: 
We're excited to share with you our recently redesigned homepage, at the same site address: DIAglobal.org. The main objectives of our redesign effort were the simplification of our message, ease of navigation, and highlighting content driven by you.

We're excited to share with you our recently redesigned homepage, at the same site address: DIAglobal.org.

The main objectives of our redesign effort were the simplification of our message, ease of navigation, and highlighting content driven by you.

New and Exciting Features

PrimeVigilance celebrates its 10th anniversary

Published date: 
13/04/2018
Summary: 
PrimeVigilance will be exhibiting and celebrating its 10th anniversary at #DIAEurope2018, raffling 10 bottles of champagne away!

PrimeVigilance will be exhibiting and celebrating its 10th anniversary at #DIAEurope2018, raffling 10 bottles of champagne away! Stop by their stand 43-44 for a chance to win a bottle of champagne!

Top Ten most popular articles on Pharmafile.com this week

It's Friday the 13th, but that doesn't change a strong showing from the industry this week as it continued to deliver some remarkable news: the pharma M&A train keeps rolling as the year goes on as Novartis announced it is to shell out $8.7 billion to snatch up gene therapy biotech AveXis, while an exciting partnership is promising to transform the hepatitis C market by offering a drug which boasts a 97% cure rate in trials for as little as $300.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches